Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi()).
Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi).
- 2013
Available online through MWHC library: 2003 - present, Available in print through MWHC library:1999-2007
We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi, Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy. Copyright 2013 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
English
1067-2516
*Enzyme Inhibitors/tu [Therapeutic Use]
*Janus Kinases/ai [Antagonists & Inhibitors]
*Polycythemia Vera/co [Complications]
*Pyrazoles/tu [Therapeutic Use]
*Skin Ulcer/dt [Drug Therapy]
*Wound Healing/de [Drug Effects]
Antimetabolites/ae [Adverse Effects]
Chronic Disease
Enzyme Inhibitors/pd [Pharmacology]
Humans
Hydroxyurea/ae [Adverse Effects]
Leg
Male
Middle Aged
Pyrazoles/pd [Pharmacology]
Skin Transplantation
Skin Ulcer/su [Surgery]
Wounds and Injuries/dt [Drug Therapy]
Wounds and Injuries/su [Surgery]
MedStar Health Research Institute
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Available online through MWHC library: 2003 - present, Available in print through MWHC library:1999-2007
We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi, Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy. Copyright 2013 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
English
1067-2516
*Enzyme Inhibitors/tu [Therapeutic Use]
*Janus Kinases/ai [Antagonists & Inhibitors]
*Polycythemia Vera/co [Complications]
*Pyrazoles/tu [Therapeutic Use]
*Skin Ulcer/dt [Drug Therapy]
*Wound Healing/de [Drug Effects]
Antimetabolites/ae [Adverse Effects]
Chronic Disease
Enzyme Inhibitors/pd [Pharmacology]
Humans
Hydroxyurea/ae [Adverse Effects]
Leg
Male
Middle Aged
Pyrazoles/pd [Pharmacology]
Skin Transplantation
Skin Ulcer/su [Surgery]
Wounds and Injuries/dt [Drug Therapy]
Wounds and Injuries/su [Surgery]
MedStar Health Research Institute
Case Reports
Journal Article
Research Support, N.I.H., Extramural